| Stereochemistry | RACEMIC |
| Molecular Formula | C10H16N2O3 |
| Molecular Weight | 212.2456 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC(C)C1(CC)C(=O)NC(=O)NC1=O
InChI
InChIKey=ZRIHAIZYIMGOAB-UHFFFAOYSA-N
InChI=1S/C10H16N2O3/c1-4-6(3)10(5-2)7(13)11-9(15)12-8(10)14/h6H,4-5H2,1-3H3,(H2,11,12,13,14,15)
| Molecular Formula | C10H16N2O3 |
| Molecular Weight | 212.2456 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Barbiturates are non-selective depressants of the central nervous system. Butabarbital is one of them, which is used under brand name butisol sodium as a sedative or hypnotic. Like other barbiturates, butabarbital is capable of producing all levels of CNS mood alteration from excitation to mild sedation, to hypnosis, and deep coma. The mechanism of action by which barbiturates exert their effect is not yet completely understood, but is assumed, that butabarbital binds at a distinct binding site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.
CNS Activity
Approval Year
Doses
AEs
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
Drug as victim
Sourcing
PubMed
Sample Use Guides
Usual adult dosage: daytime sedative - 15 to 30 mg, 3 or 4 times daily.
Bedtime hypnotic - 50 to 100 mg. Preoperative sedative - 50 to 100 mg, 60 to 90 minutes before surgery.
Usual pediatric dosage: preoperative sedative - 2 to 6 mg/kg maximum 100 mg.
Route of Administration:
Oral
